ID   STA-ET-1
AC   CVCL_9681
SY   STA-ET1; STAET1; St. Anna Kinderspital-Ewing Tumor-1
DR   EFO; EFO_0002862
DR   cancercelllines; CVCL_9681
DR   Cosmic; 2250473
DR   GEO; GSM510010
DR   IARC_TP53; 23641
DR   Progenetix; CVCL_9681
DR   Wikidata; Q54955761
RX   PubMed=8378080;
RX   PubMed=9393981;
RX   PubMed=15150091;
RX   PubMed=19787792;
RX   PubMed=21822310;
RX   PubMed=25223734;
RX   PubMed=26428435;
CC   From: Children's Cancer Research Institute; Vienna; Austria.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; PubMed=25223734).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=9393981).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Derived from site: In situ; Bone, humerus; UBERON=UBERON_0000976.
ST   Source(s): PubMed=19787792
ST   Amelogenin: X
ST   D16S539: 12
ST   D18S51: 14,18
ST   D19S433: 14,15
ST   D21S11: 28,29
ST   D2S1338: 17
ST   D3S1358: 15,17
ST   D5S818: 13
ST   D8S1179: 8,15
ST   FGA: 21,24
ST   SE33: 14,16
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 17,19
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S862 ! SAL1
OI   CVCL_F122 ! SAL2
SX   Female
AG   13Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 05-10-23; Version: 21
//
RX   PubMed=8378080;
RA   Kovar H., Auinger A., Jug G., Aryee D.N.T., Zoubek A.,
RA   Salzer-Kuntschik M., Gadner H.;
RT   "Narrow spectrum of infrequent p53 mutations and absence of MDM2
RT   amplification in Ewing tumours.";
RL   Oncogene 8:2683-2690(1993).
//
RX   PubMed=9393981; DOI=10.1038/sj.onc.1201397;
RA   Kovar H., Jug G., Aryee D.N.T., Zoubek A., Ambros P.F., Gruber B.,
RA   Windhager R., Gadner H.;
RT   "Among genes involved in the RB dependent cell cycle regulatory
RT   cascade, the p16 tumor suppressor gene is frequently lost in the Ewing
RT   family of tumors.";
RL   Oncogene 15:2225-2232(1997).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=25223734; DOI=10.1158/2159-8290.CD-14-0622;
RA   Tirode F., Surdez D., Ma X.-T., Parker M., Le Deley M.-C., Bahrami A.,
RA   Zhang Z.-J., Lapouble E., Grossetete-Lalami S., Rusch M., Reynaud S.,
RA   Rio-Frio T., Hedlund E., Wu G., Chen X., Pierron G., Oberlin O.,
RA   Zaidi S., Lemmon G., Gupta P., Vadodaria B., Easton J., Gut M.,
RA   Ding L., Mardis E.R., Wilson R.K., Shurtleff S., Laurence V.,
RA   Michon J., Marec-Berard P., Gut I.G., Downing J.R., Dyer M.A.,
RA   Zhang J.-H., Delattre O.;
RT   "Genomic landscape of Ewing sarcoma defines an aggressive subtype with
RT   co-association of STAG2 and TP53 mutations.";
RL   Cancer Discov. 4:1342-1353(2014).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//